Shares of Imagion Biosystems (ASX:IBX) jumped as much as 9% to AU$0.085, their highest since 23 July 2021.
The medical devices maker has signed an agreement with biopharmaceutical firm Global Cancer Technology (GCT) to develop nanoscintillator technology for treating breast cancer.
IBX said GCT’s nanoscintillator tech has the potential to deliver a more localised and effective dose of the drug product to treat cancers.
More than 9.8 million shares got traded today.
1BX is down 46.2% this year, as of the last close but closed 3.846% up today,
Global Cancer Technology is offering pre-IPO shares to accredited investors. Please contact us if you need more investment information 👉 Healthcare investment opportunities